
Avian Influenza and Worker Safety: Understanding and Managing the H5N1 Risk
The rise of highly pathogenic avian influenza (HPAI), particularly the H5N1 strain, presents serious challenges to worker safety across several industries. From poultry farms and veterinary clinics to laboratories and wildlife agencies, anyone working in close contact with birds—or even pets that come into contact with infected animals—may be at risk of exposure.
The Integrated Bioscience and Built Environment Consortium ( IBEC ) brought together experts to examine the occupational health risks associated with H5N1 and to discuss strategies for protecting frontline workers. Speakers highlighted critical risk pathways, personal protective measures, mental health considerations, and lessons learned from recent research and outbreaks.
Who's Most at Risk?
Several job sectors are particularly vulnerable to H5N1 exposure, including:
Emerging evidence shows that avian influenza can affect domestic and wild cats—sometimes fatally. Dr. Kristen Coleman of the University of Maryland School of Public Health shared research showing that 607 feline deaths linked to AIV have been recorded globally over the past decade across 18 countries and 12 species of felines. Transmission often occurs when cats consume infected birds or raw poultry products. Contaminated raw chicken feed and dairy milk have been implicated in both domestic and captive animals, including tigers.
Additionally, Dr. Maggie Baldwin from the Colorado Department of Agriculture cited two recent cases in indoor-only domestic cats in Colorado, with no known exposure to infected animals. These incidents suggest new and less-understood transmission routes and reinforce the importance of vigilance even in seemingly low-risk scenarios.
How to Reduce Risk: Key Strategies
Protecting workers from H5N1 requires a layered, proactive approach:
1. Training and Awareness
Educating employees about transmission pathways, symptoms, and protective measures is essential. This includes pet safety, as infected cats may serve as early indicators of outbreaks in the area.
Basic pet-related guidance includes:
If a pet tests positive, it may indicate local viral circulation.
2. Personal Protective Equipment (PPE)
High-risk workers should be equipped with:
Proper training and compliance monitoring are just as important as PPE availability.
3. Strong Biosecurity and Hygiene Protocols
4. Surveillance and Monitoring
Active surveillance in bird populations—both domestic and wild—is key to early detection and response. Public-private collaboration is vital for timely data sharing and coordinated action.
5. Vaccination and Medical Monitoring
Although no commercial H5N1 vaccine for humans currently exists, seasonal flu vaccination can help reduce co-infection risks. For high-risk roles, employers should consider regular health surveillance and exposure testing.
6. Designated Outbreak Coordinators
For organizations in high-risk sectors, appointing an H5N1 case manager to oversee protocols and incident response can improve outbreak management and reduce confusion.
Enhancing Protection Through Workplace Controls
Employers should implement foundational occupational health strategies:
What to Do During an Outbreak
If an H5N1 outbreak occurs, rapid action is crucial:
Final Thoughts
Avian influenza is more than a veterinary or agricultural issue, it's a growing occupational health concern that requires a multi-sector response. Key actions include prioritizing worker training and protection, maintaining robust biosecurity, and responding swiftly and transparently during outbreaks.
The threat of H5N1 will continue to evolve. Ongoing research, like that of Dr. Coleman and Dr. Baldwin, surveillance programs, and interagency collaboration will be essential to minimizing harm and safeguarding both public and occupational health.
Questions? Reach out to our Health & Safety team today!
Visit 3BL Media to see more multimedia and stories from Antea Group
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
10 hours ago
- CBS News
Illinois ComEd customers may be paying for electrical waste, company says; utility disputes claim
A company that measures and tracks electrical grids across America says that the ComEd grid in Illinois has the highest electrical waste in the country, and customers are paying for it. Ever since a supplier rate change took effect, ComEd customers have reported seeing their bills double or more. Maryland-based Whisker Labs has installed nearly 1 million Ting sensors nationwide, and about 51,000 in the greater Chicago area. The sensors measure and track electrical grid resiliency and energy efficiency in regards to power delivered to homes. "This is effectively another surcharge that nobody knows about," said engineer and CEO Bob Marshall. Marshall developed the Ting sensors to help prevent electrical fires after his sister-in-law's home burned down from one in 2015. But the network of sensors also monitors the power quality going into all of the homes where Ting sensors are installed. That measurement is made through a metric called Total Harmonic Distortion, which measures the level of "noise" or "distortion" in the electricity. The higher the THD levels, the less energy efficient the electricity is and the more damage it could cause to appliances and devices, according to Whisker Labs. The company says industry standards specify that THD levels should remain below 8%. "They all measure the same thing, the same way," he explained. "Chicago is very unique. Usually, I mean, less than 2% of homes across the country have distorted power. But 40% of the home in Chicago have distorted power, and that is costing consumers. It can cost several hundred dollars per year." Marshall said the distorted power means Chicago customers could be paying for energy waste. He said they see a similar pattern in the Denver area, but he said it's not as bad as the distortion they're measuring in ComEd territory. ComEd said in a statement that it "strongly questions" Whisker Lab's claims, in part because the company hasn't shared their original data, and called their claims about "harmonics" causing electrical bills to be higher "unsubstantiated." Marshall said energy waste is worse in Chicago neighborhoods where the map shows red, maroon and purple. Suburbs like Northbrook, Schaumburg and Country Club Hills also show significant distortion, according to their data. "We can't speak to the cause. I mean, we know it's originating on the grid. It's not coming from individual homes because there are particular communities that have this problem," Marshall said. ComEd didn't offer a theory for why the sensor readings look different for our area, but said in a statement that Illinois customers have some of the lowest average electricity bills in the Midwest. "Our hope is to use data for good to help utilities, help communities understand where there are challenges on the grid, and address them proactively before they cause damage or catastrophes," Marshall said. Marshall noted that when it comes to power outages, they've found that ComEd's reliability is pretty good compared to the rest of the country. ComEd strongly questions many of Whisker Lab's claims about harmonics and about the capability of their in-home sensors both because many of the metrics they reference are not recognized by the electric power industry and because Whisker Labs has refused to share either its methodology or original measurement data with us. The Ting sensors used by WL are a measure of electrical signals in the home, not the grid or its reliability. Further, their claims about harmonics inflating customer bills are unsubstantiated. In fact, ComEd's investments in the grid, as well as its work to manage costs, have contributed to our Illinois customer having among the lowest average electricity bills in the Midwest.
Yahoo
20 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
20 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data